The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

##STR00001##

Ligands for use with catalyst compositions used in hydroformylation reactions are described herein. The ligands are used with various solvents and achieve an increase in isoselectivity with an increase in temperature.

An organic compound, an electroluminescent material and its application are provided in the present disclosure. The organic compound includes a structure: ##STR00001## X is selected from O, S, N—R.sub.N1, and CR.sub.C1R.sub.C2; Y is selected from O, S, N—R.sub.N2, CR.sub.C3R.sub.C4, O═S═O, SiR.sub.S1R.sub.S2, O═P—Ar.sub.1, and S═P—Ar.sub.2, R.sub.N1, R.sub.N2, R.sub.C1, R.sub.C2, R.sub.C3, R.sub.C4, R.sub.S1, and R.sub.S2 are each independently selected from C1˜C20 linear or branched alkyl, C6˜C40 aryl, and C3˜C40 heteroaryl; Ar.sub.1 and Ar.sub.2 are each independently selected from C6˜C40 aryl and C3˜C40 heteroaryl; L.sub.1, L.sub.2, L.sub.3, L.sub.4, and L.sub.5 are each independently selected from a single bond, C6˜C40 arylene, and C3˜C40 heteroarylene; R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are each independently selected from deuterium, C1˜C20 linear or branched alkyl, C1˜C20 alkoxy, C1˜C20 alkylthio, C3˜C20 cycloalkyl, C6˜C40 aryl, C3˜C40 heteroaryl, and C6˜C40 arylamino; and n.sub.1, n.sub.2, n.sub.3, n.sub.4, n.sub.5, m.sub.1, m.sub.2, m.sub.3, m.sub.4, and m.sub.5 are integers each independently selected from 0-2.

Provided is an organic electroluminescent element having high efficiency, a long lifetime, and bending resistance. An organic electroluminescent element includes a light emitting layer and an electron transport layer adjacent to the light emitting layer between a positive electrode and a negative electrode. A host compound of the light emitting layer has an ionization potential deeper than that of a light emitting dopant of the light emitting layer by 0.3 eV or more. At least one organic compound contained in the electron transport layer has a molecular dipole moment of 6.0 debye or more.

Disclosed is a laser device containing a. compound represented by the following formula in a light-emitting layer, R.sup.1 and R.sup.5 each represent a substituent having a positive Hammett's σ.sub.p value, and R.sup.2 to R.sup.4, and R.sup.6 to R.sup.15 each represent a hydrogen atom or a substituent.

##STR00001##

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. ##STR00001##

Tridentate platinum, palladium, and gold complexes of Formulas A-I and A-II and tridentate iridium and rhodium compounds of Formulas B-I, B-II, and B-III suitable for delayed fluorescent and phosphorescent or phosphorescent emitters in display and lighting applications. ##STR00001##

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.